Sign Up:

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

  Register

Overview

Already Registered? Click Here

Managing Multiple Biomarker Therapeutic Development

Tuesday, July 16th, 2019
8 am PT, 11 am ET, 17:00 CET

 

For the past two decades, the paradigm in the field has been “one biomarker, one drug,” leading to the development of many targeted therapies and companion diagnostics. As molecular profiling of various cancer types expands, we imagine the use of multiple biomarkers for a combination therapy, like a targeted therapy and immunotherapy together, or even for a monotherapy.

In this roundtable our panelists will discuss assessing the validity of biomarkers to inform drug development and potential combination therapies. Key considerations include predictive testing of biomarkers, analytical methods, drug-diagnostic co-development and potential reimbursement considerations. Dr. Kelly Sullivan, Solutions Manager, N-of-One (a QIAGEN Company) will moderate the discussion with Jeffrey Waldron, Executive Director, Precision Medicine Connective, and Dr. Diana Merino, Science Policy Analyst at Friends of Cancer Research.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

Presenters

Presenter
Diana Merino, PhD
Science Policy Analyst
Friends of Cancer Research
View Biography
Presenter
Jeffrey Waldron
Executive Director
PM Connective
View Biography
Presenter
Kia Katchar, PhD
Director, Companion Diagnostics
Merck
View Biography
Presenter
E. Kelly Sullivan, PhD
Solutions Manager
N-of-One, Inc.
View Biography